Objective: MIAMI is a prospective multicenter clinical study designed to investigate the relationship between C-IMT progression and changes in circulating markers of inflammation, coagulation and endothelial dysfunction in patients with stable CAD treated for two years with 20 mg/day atorvastatin. Methods: C-IMT, blood lipids and soluble markers were measured at baseline, at the 12th month and at the end of the study in eighty-five patients. Results: Atorvastatin induced C-IMT regression. Fibrinogen, TFPI-total, sICAM-1, sE-selectin, IL-8 and vWF, but not hs-CRP, IL-18, TFPI-free, sVCAM-1, IL-6, TNF-α and sCD40L, decreased upon treatment. Changes in lipids did not correlate with C-IMT regression. Changes in single soluble markers correlated poorly with C-IMT regression, but strongly when combined in relevant composite scores (inflammation/coagulation-score, endothelial activation-score, soluble markers-score and total-score). Conclusions: In patients with stable CAD, a moderate dose of atorvastatin was associated with regression of C-IMT. This effect was correlated with changes of inflammation, thrombosis and endothelial dysfunction profiles. Funding: Partial support by a grant from Pfizer- Italia

The MIAMI Study (Markers of inflammation and Atorvastatin effect in previous myocardial infarction) : results of a prospective, multicenter study / B. Porta, D. Baldassarre, M. Camera, M. Amato, M. Arquati, E. Tremoli, M. Cortellaro, F. Perego. - In: JOURNAL OF CLINICAL LIPIDOLOGY. - ISSN 1933-2874. - 2:5(2008), pp. s91-s92. ((Intervento presentato al 7. convegno International symposium on multiple risk factors in cardiovascular diseases : prevention and intervention, health policy tenutosi a Venezia nel 2008.

The MIAMI Study (Markers of inflammation and Atorvastatin effect in previous myocardial infarction) : results of a prospective, multicenter study

B. Porta
Primo
;
D. Baldassarre
Secondo
;
M. Camera;E. Tremoli;M. Cortellaro
Penultimo
;
F. Perego
Ultimo
2008

Abstract

Objective: MIAMI is a prospective multicenter clinical study designed to investigate the relationship between C-IMT progression and changes in circulating markers of inflammation, coagulation and endothelial dysfunction in patients with stable CAD treated for two years with 20 mg/day atorvastatin. Methods: C-IMT, blood lipids and soluble markers were measured at baseline, at the 12th month and at the end of the study in eighty-five patients. Results: Atorvastatin induced C-IMT regression. Fibrinogen, TFPI-total, sICAM-1, sE-selectin, IL-8 and vWF, but not hs-CRP, IL-18, TFPI-free, sVCAM-1, IL-6, TNF-α and sCD40L, decreased upon treatment. Changes in lipids did not correlate with C-IMT regression. Changes in single soluble markers correlated poorly with C-IMT regression, but strongly when combined in relevant composite scores (inflammation/coagulation-score, endothelial activation-score, soluble markers-score and total-score). Conclusions: In patients with stable CAD, a moderate dose of atorvastatin was associated with regression of C-IMT. This effect was correlated with changes of inflammation, thrombosis and endothelial dysfunction profiles. Funding: Partial support by a grant from Pfizer- Italia
Settore MED/09 - Medicina Interna
Settore BIO/14 - Farmacologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
porta.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 157.52 kB
Formato Adobe PDF
157.52 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/62537
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact